Shares of BioSpecifics Technologies Corp (NASDAQ:BSTC) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Brokers have set a 1-year consensus target price of $72.00 for the company and are expecting that the company will post $0.39 earnings per share for the current quarter, according to Zacks. Zacks has also given BioSpecifics Technologies Corp an industry rank of 120 out of 265 based on the ratings given to its competitors.

Several equities analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of BioSpecifics Technologies Corp from a “hold” rating to a “sell” rating in a report on Monday, May 15th. BidaskClub lowered shares of BioSpecifics Technologies Corp from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd.

BioSpecifics Technologies Corp (NASDAQ BSTC) traded up 1.44% on Tuesday, reaching $48.72. The company had a trading volume of 41,515 shares. BioSpecifics Technologies Corp has a one year low of $35.79 and a one year high of $58.79. The firm has a market capitalization of $349.37 million, a price-to-earnings ratio of 29.89 and a beta of 1.76. The company’s 50 day moving average is $49.83 and its 200-day moving average is $52.04.

ILLEGAL ACTIVITY NOTICE: “Zacks: BioSpecifics Technologies Corp (BSTC) Given Average Rating of “Strong Buy” by Analysts” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/08/08/zacks-biospecifics-technologies-corp-bstc-given-average-rating-of-strong-buy-by-analysts.html.

Several institutional investors have recently added to or reduced their stakes in the stock. American International Group Inc. raised its position in BioSpecifics Technologies Corp by 7.1% in the first quarter. American International Group Inc. now owns 3,327 shares of the biopharmaceutical company’s stock valued at $182,000 after buying an additional 222 shares during the last quarter. Eagle Global Advisors LLC raised its position in BioSpecifics Technologies Corp by 13.9% in the first quarter. Eagle Global Advisors LLC now owns 9,946 shares of the biopharmaceutical company’s stock valued at $545,000 after buying an additional 1,210 shares during the last quarter. Algert Global LLC raised its position in BioSpecifics Technologies Corp by 5.5% in the first quarter. Algert Global LLC now owns 7,924 shares of the biopharmaceutical company’s stock valued at $434,000 after buying an additional 410 shares during the last quarter. Chicago Equity Partners LLC raised its position in BioSpecifics Technologies Corp by 37.3% in the first quarter. Chicago Equity Partners LLC now owns 13,115 shares of the biopharmaceutical company’s stock valued at $719,000 after buying an additional 3,565 shares during the last quarter. Finally, Wedge Capital Management L L P NC acquired a new position in BioSpecifics Technologies Corp during the first quarter valued at about $2,093,000. Hedge funds and other institutional investors own 54.97% of the company’s stock.

BioSpecifics Technologies Corp Company Profile

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.

Get a free copy of the Zacks research report on BioSpecifics Technologies Corp (BSTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioSpecifics Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp and related companies with MarketBeat.com's FREE daily email newsletter.